Pfizer (PFE) CEO Albert Bourla Receives 24-Unit Deferred Award

What Happened

• Albert Bourla, Chairman & CEO of Pfizer Inc., was granted 24 units classified as a derivative award on July 31, 2026. Each unit was valued at $25.01, for a total reported value of $600. The filing reports an award/acquisition (code A) of phantom-share units rather than an open-market stock purchase.

Key Details

• Transaction date and price: 2026-07-31, 24 units at $25.01 each (total $600).
• Transaction type: Award/Grant (derivative phantom-share units).
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F1 — each unit equals one phantom share of common stock; F2 — units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash upon separation from service, and may be transferred by the reporting person into an alternative investment account at any time.
• Filing: Reported on Form 4, filed 2026-08-03 (timely relative to the reported transaction date).

Context

• These are phantom-share units (deferred cash-settled awards), not immediate common-stock ownership. They typically convert to cash after separation from service or can be moved into an alternate investment account, so they do not directly increase voting shares or immediate market exposure.
• The award value is small ($600) and is a routine compensation-related grant rather than a market-direction trade.